Detalhe da pesquisa
1.
Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis.
J Clin Apher
; 34(4): 423-433, 2019 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-30817043
2.
Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.
Arterioscler Thromb Vasc Biol
; 36(9): 2019-27, 2016 09.
Artigo
Inglês
| MEDLINE | ID: mdl-27417585
3.
Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial.
Eur Heart J
; 37(48): 3588-3595, 2016 Dec 21.
Artigo
Inglês
| MEDLINE | ID: mdl-27572070
4.
Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.
Circulation
; 128(24): 2567-76, 2013 Dec 17.
Artigo
Inglês
| MEDLINE | ID: mdl-24056686
5.
Immunoadsorption in patients with chronic inflammatory demyelinating polyradiculoneuropathy with unsatisfactory response to first-line treatment.
Eur Neurol
; 66(4): 183-9, 2011.
Artigo
Inglês
| MEDLINE | ID: mdl-21912134
6.
CytoResc - "CytoSorb" Rescue for critically ill patients undergoing the COVID-19 Cytokine Storm: A structured summary of a study protocol for a randomized controlled trial.
Trials
; 21(1): 577, 2020 Jun 26.
Artigo
Inglês
| MEDLINE | ID: mdl-32586396